Varicella-Zostbr Virus Infection in a Pediatric Oncology Unit

Kirk, J A; Menser, Margaret A.; Bergin, Mary; Stevens, Michael; Silva, L M De

doi:10.1097/00006454-198807000-00019

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal method of varicella prophylaxis in high‐risk individuals has been ZIG (made from pooled immunoglobulin). In Australia it has been effective in reducing the clinical attack rate to 13% (compared with 80–90% without prophylaxis) following household exposure 5 . This is in contrast to overseas experience where the attack rate among ZIG recipients has been as high as 65% 6 .…”

Section: Discussionmentioning

confidence: 99%

Varicella vaccine in non‐immune household contacts of children with cancer or leukaemia

Kappagoda¹,

Shaw

Burgess³

et al. 1999

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Varicella vaccine in non‐immune household contacts of children with cancer or leukaemia

Kappagoda¹,

Shaw

Burgess³

et al. 1999

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

An Economic Evaluation of Varicella Vaccine for Pediatric Liver and Kidney Transplant Recipients

Kitai

King²,

Gafni³

1993

Clinical Infectious Diseases

View full text Add to dashboard Cite

To evaluate the potential benefit of varicella vaccine for pediatric liver and kidney transplant patients, we determined the consequences of varicella susceptibility for a cohort of susceptible children (n = 44) who received transplants between July 1986 and June 1990 at the Hospital for Sick Children, Toronto. Costs of these consequences were compared with costs with a hypothetical varicella vaccination program in place. The median follow-up was 11.4 months (range, 2-50 months). Total costs in Canadian dollars to the health service without a program were for varicella-related hospital stay ($135,675) and varicella-zoster immune globulin ($4,322). Costs to parents were for lost time ($13,590) and transport ($414). Assuming a vaccine cost of $30/dose and a 90% vaccine efficacy, a pretransplantation vaccination program would have cost $16,205 and saved $3,132/child ($304 for families and $2,828 for the health service) during the study period. Varicella vaccination prior to solid organ transplantation should reduce morbidity in pediatric recipients and provide considerable savings for families and the health system.

show abstract

The Frequency and Consequences of Varicella Exposure and Varicella Infection in Children Receiving Maintenance Therapy for Acute Lymphoblastic Leukemia

Buda¹,

Tubergen²,

Levin³

1996

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

Varicella-Zostbr Virus Infection in a Pediatric Oncology Unit

Cited by 6 publications

References 0 publications

Varicella vaccine in non‐immune household contacts of children with cancer or leukaemia

Varicella vaccine in non‐immune household contacts of children with cancer or leukaemia

An Economic Evaluation of Varicella Vaccine for Pediatric Liver and Kidney Transplant Recipients

The Frequency and Consequences of Varicella Exposure and Varicella Infection in Children Receiving Maintenance Therapy for Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About